Invitae Corp. will acquire ArcherDX Inc. for $1.4bn to create a single cancer diagnostics "platform" combining hereditary testing, tumor profiling, liquid biopsy technologies and genetic testing services.
Invitae is a San Francisco-based medical genetics company focused on aggregating genetic testing information into a single service to increase the quality and efficiency of genetic testing